Cresco Labs (CRLBF) Income from Non-Controlling Interests (2020 - 2026)
Cresco Labs (CRLBF) posted Income from Non-Controlling Interests of -$3.9 million for Q1 2026, down 189.64% on a QoQ basis from -$1.4 million in Q4 2025, and down 391.52% year-over-year from $1.4 million in Q1 2025.
Cresco Labs (CRLBF) Income from Non-Controlling Interests (2020 - 2026) Analysis & Trends
Cresco Labs' Income from Non-Controlling Interests history runs 7 years deep, the most recent figure standing at -$3.9 million for Q1 2026.
- Quarterly Income from Non-Controlling Interests fell 391.52% year-over-year to -$3.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.8 million (down 177.69% YoY) and the FY2025 annual result came in at -$4.6 million, down 133.24% from the prior year.
- Income from Non-Controlling Interests was -$3.9 million for Q1 2026 at Cresco Labs, down from -$1.4 million in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $6.5 million in Q3 2022 and bottomed at -$19.3 million in Q4 2022.
- A 5-year average of -$162058.8 and a median of $2.2 million in 2023 frame the typical range for Income from Non-Controlling Interests.
- Annual changes were most pronounced in 2022 — Income from Non-Controlling Interests sank 783.66% — and 2024, when it surged 278.19%.
- Cresco Labs' Income from Non-Controlling Interests stood at -$19.3 million in 2022, then surged by 111.58% to $2.2 million in 2023, then jumped by 115.45% to $4.8 million in 2024, then sank by 128.29% to -$1.4 million in 2025, then tumbled by 189.64% to -$3.9 million in 2026.
- Business Quant data shows CRLBF's Income from Non-Controlling Interests at -$3.9 million in Q1 2026, -$1.4 million in Q4 2025, and -$4.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 395,346.10 |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | -12.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Cresco Labs | 245.85 Mn | 182.28 Mn | 75.45 Mn | -3.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.94 Mn |
| Dec 31, 2025 | -1.36 Mn |
| Sep 30, 2025 | -4.91 Mn |
| Jun 30, 2025 | 2.44 Mn |
| Mar 31, 2025 | -802,000.00 |
| Dec 31, 2024 | 4.81 Mn |
| Sep 30, 2024 | 2.85 Mn |
| Jun 30, 2024 | 3.15 Mn |
| Mar 31, 2024 | 3.14 Mn |
| Dec 31, 2023 | 2.23 Mn |
| Sep 30, 2023 | 2.13 Mn |
| Jun 30, 2023 | -6.93 Mn |
| Mar 31, 2023 | -1.76 Mn |
| Dec 31, 2022 | -19.29 Mn |
| Sep 30, 2022 | 6.54 Mn |
| Jun 30, 2022 | 5.25 Mn |
| Mar 31, 2022 | 3.71 Mn |
| Dec 31, 2021 | 2.82 Mn |
| Sep 30, 2021 | 7.19 Mn |
| Jun 30, 2021 | 7.48 Mn |